Vistagen Therapeutics, Inc. (VTGN)

Several significant events have impacted Vistagen Therapeutics' stock price in the past six months. On December 17, 2025, the PALISADE-3 Phase 3 study of fasedienol failed to achieve its primary endpoint, leading to analyst downgrades and a stock price drop. On January 15, 2026, a federal securities class action lawsuit was filed against Vistagen Therapeutics, Inc., alleging violations of the Securities Exchange Act of 1934. On February 12, 2026, Vistagen reported its Fiscal Year 2026 Third Quarter Financial Results and provided a corporate update. In March 2026, the company participated in investor conferences. Over the last year, the stock's price has decreased by 76.88% as of March 26, 2026, with a 52-week high of $5.14 and a 52-week low of $0.43. As of March 26, 2026, the share price was $0.60, a decline of 77.00% from March 27, 2025.

Traditional demand seasonality is not applicable to Vistagen Therapeutics, Inc. as a biopharmaceutical company. The demand for its investigational drug candidates is driven by clinical trial progress, regulatory milestones, and the prevalence of the conditions they aim to treat, rather than seasonal consumer patterns. Stock price seasonality reflects investor behavior and market trends, not the seasonality of product demand.

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on neuroscience, operating within the Healthcare sector and the Pharmaceutical preparations industry. The company develops therapies for psychiatric and neurological disorders, utilizing nose-to-brain neurocircuitry. Its pipeline includes intranasal product candidates called pherines, designed to activate chemosensory neurons in the nasal cavity to impact neurocircuitry in the olfactory system and the brain. Key product candidates include Fasedienol (PH94B) for social anxiety disorder, Itruvone (PH10) for depression disorders, AV-101 for depression and neurological disorders, PH15 for cognition improvement, PH80 for vasomotor symptoms, and PH284 for wasting syndrome.

Vistagen Therapeutics, Inc. is headquartered in South San Francisco, California, United States. Its primary operational base and focus are within the United States, although it is listed on NASDAQ (US) and mentioned in relation to the Mexico Stock Exchange.

Vistagen Therapeutics' brand reputation has been significantly impacted by the failure of its PALISADE-3 Phase 3 study for fasedienol in December 2025, leading to a decline in the company's stock price and analyst downgrades. The initiation of a securities class action lawsuit in January 2026, alleging misleading statements about the PALISADE-3 trial, has also negatively affected the company's reputation.

Vistagen Therapeutics, Inc. has a diverse ownership structure. Institutional shareholders hold approximately 34.71% of the company's stock, while insiders hold about 69.84%. Another source indicates that retail investors own 49% of the company, with institutions holding 23% and insiders owning less than 1%. Major institutional owners include Orbimed Advisors LLC, Vanguard Group Inc, ADAR1 Capital Management, LLC, StemPoint Capital LP, Jane Street Group, Llc, Ikarian Capital, LLC, Citadel Advisors Llc, BlackRock, Inc., and Susquehanna International Group, Llp. Venrock Healthcare Capital Partners II LP is the largest individual shareholder, owning 20.64 million shares, representing 52.09% of the company.